

FEB 25 2004

K040157

510(k) Summary

Introduction	According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.
---------------------	--

Submitter name, address, contact	Roche Diagnostics 9115 Hague Road Indianapolis, IN 46250 317-521-3723 Contact Person: Theresa M. Ambrose Date Prepared: January 22, 2004
---	---

Device Name	Proprietary name: Elecsys® C-Peptide CalCheck Common name: C-Peptide CalCheck Classification name: Single (specified) analyte controls (assayed and unassayed)
--------------------	--

Predicate device	The Elecsys® C-Peptide CalCheck is substantially equivalent to the currently marketed Elecsys® SHBG CalCheck (K031698).
-------------------------	---

Device Description	The Elecsys® C-Peptide CalCheck is a lyophilized product consisting of synthetic human C-Peptide in a buffered equine serum matrix. During manufacture, the analytes are spiked into the matrix at the desired concentration levels.
---------------------------	--

Intended use	The Elecsys® C-Peptide CalCheck is intended for use in the verification of the calibration established by the Elecsys® C-Peptide reagent on the Elecsys® immunoassay systems.
---------------------	---

Continued on next page

510(k) Summary, Continued

Comparison to predicate device

The Elecsys® C-Peptide CalCheck is substantially equivalent to the currently marketed Elecsys® SHBG CalCheck (K031698). The below tables compare Elecsys® C-Peptide CalCheck with the predicate device, Elecsys® SHBG CalCheck (K031698).

Similarities

Characteristic	Elecsys® C-Peptide CalCheck	Predicate device: Elecsys® SHBG CalCheck
Intended Use	Elecsys® C-Peptide CalCheck is intended for use in the verification of the calibration established by the Elecsys® C-Peptide reagent on the Elecsys® immunoassay systems.	Elecsys® SHBG CalCheck is intended for use in the verification of the calibration established by the Elecsys® SHBG reagent on the Elecsys® immunoassay systems.
Levels	Three	same
Format	Lyophilized	same
Handling	Reconstitute with exactly 1.0 mL distilled water and allow to stand closed for 15 minutes.	same
Stability	<u>Unopened:</u> <ul style="list-style-type: none">• Store at 2-8°C until expiration date <u>Reconstituted:</u> <ul style="list-style-type: none">• 20 – 25 °C : 4 hrs	same

Continued on next page

510(k) Summary, Continued

Differences

Characteristic	Elecsys® C-Peptide CalCheck	Predicate device: Elecsys® SHBG CalCheck
Matrix	Buffered horse serum with added C-Peptide.	Buffered horse serum and human serum with added SHBG

Performance Characteristics

The Elecsys® C-Peptide CalCheck was evaluated for value assignment and stability.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration
2098 Gaither Road
Rockville MD 20850

FEB 25 2004

Theresa M. Ambrose, Ph.D.
Regulatory Principal
Centralized Diagnostics Regulatory Submissions
Roche Diagnostics Corporation
9115 Hague Road
P.O. Box 50457
Indianapolis, IN 46250-0457

Re: k040157
Trade/Device Name: Elecsys® C-Peptide CalCheck
Regulation Number: 21 CFR 862.1660
Regulation Name: Quality control material (assayed and unassayed)
Regulatory Class: Class I
Product Code: JJX
Dated: January 22, 2004
Received: January 23, 2004

Dear Dr. Ambrose:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of *In Vitro* Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>.

Sincerely yours,

A handwritten signature in cursive script that reads "Jean M. Cooper MS, D.V.M.".

Jean M. Cooper, MS, D.V.M.

Director

Division of Chemistry and Toxicology

Office of *In Vitro* Diagnostic Device

Evaluation and Safety

Center for Devices and

Radiological Health

Enclosure

Indications for Use Statement

510(k) Number (if known): N/A K040157

Device Name: Elecsys® C-Peptide CalCheck

Indications For Use:

The Elecsys® C-Peptide CalCheck is intended for use in the verification of the calibration established by the Elecsys® C-Peptide reagent on the Elecsys® immunoassay systems.

Prescription Use X
(Per 21 CFR 801.109)

OR

Over-The-Counter Use _____

(Optional Format 1-2-96)

Carol C Benson
Division Sign-Off

Office of In Vitro Diagnostic Device
Evaluation and Safety

510(k) K040157